Barr changes at top
This article was originally published in The Tan Sheet
Executive SummaryBruce Downey remains chairman and CEO of Barr Pharmaceuticals, but sheds the president and chief operating officer posts he picked up when Paul Bisaro resigned to take over at Watson in August 2007, the Montvale, N.J.-based firm says March 28. VP-Global Quality and Regulatory Affairs Christine Mundkur moves up to CEO of Barr Laboratories, the company's global generics business, which manufactures and markets the Plan B (levonorgestrel) emergency contraceptive. Answering to Mundkur, Michael Bogda becomes president and COO and Timothy Sawyer becomes executive VP-global generic sales and marketing. G. Frederick Wilkinson is named CEO of Barr's proprietary products business Duramed, and will also be responsible for Barr's global business development, including generic, proprietary and biologics activities. Barr Pharmaceuticals CFO Bill McKee has new responsibilities for coordinating global tax planning and creating cost efficiencies, according to the firm's release...
You may also be interested in...
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.
Successfully acquired by Colgate-Palmolive on 31 January, Hello quickly made a statement with the launch of a CBD oral-care range and its first go at lip care, CBD Vegan Lip Balm. Available exclusively through Ulta Beauty, the CBD products have the potential to score well with younger consumers interested in natural ingredients, eco-friendly packaging and, of course, cannabis-based innovations.
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.